Compare BridgeBio Pharma Inc (BBIO) vs e l f Beauty Inc (ELF) Price & Performance

BridgeBio Pharma (BBIO) trades at $83.08, down 3.27% today, near its 52-week high. The stock shows bullish technical momentum with strong moving averages, while fundamentals reveal rapid revenue growth to $502M in 2025 but persistent losses with a -144.4% net margin. Recent news highlights regulatory approvals for acoramidis and a $1B preferred equity raise to fund launches, driving positive sentiment despite earnings misses.

Outlook remains speculative with high execution risk; analyst consensus is strongly bullish (92% buy) targeting $104.57, but profitability challenges and heavy cash burn require successful pipeline commercialization to justify valuation. Key near-term catalysts include FDA decisions on BBP-418 and encaleret in 2026.

ELF Beauty trades at $75.10, down 2.15% on the day, with a bullish technical signal from moving averages. The company reported strong revenue of $1.31 billion in 2025 and has beaten earnings estimates for three consecutive quarters. Recent news highlights brand expansion and a 32% stock jump in June 2026, though growth is transitioning as the core brand softens.

The outlook is mixed: analyst consensus is evenly split between Buy and Hold, with a $74.42 price target near the current price. Upside potential exists from skincare and international expansion, but risks include cost pressures, tariff exposure, and the need to sustain double-digit sales growth amid competitive dynamics.